Organogenesis Holdings Inc. ORGO
Set alert
As of Nov 2, 1:03 PM ET
- YTD
- -85.61%
- 1 year
- -82.46%
- Open
- 0.78
- Prev close
- 0.7681
- Mkt cap
- 96.03M
- Vol
- 404.15K
- Avg vol
- 832.94K
- EPS
- -0.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7301
- High
- 0.80
- Forward P/E
- -79.50
- Beta
- 1.60
- Short ratio
- 11.35
- Inst. own
- 48.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.44
- 200-d avg
- 2.93
- 1y target
- 5.00
News
-
2 weeks ago benzinga.com
Organogenesis Holdings Announces Publication Of Results From PREPARE, Multicenter, RCT Evaluating PuraPlyAM Plus SoC Compared To SoC Alone In Hard-To-Heal Diabetic Foot Ulcers
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced…
2 weeks ago globenewswire.com
Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot Ulcers
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and…
2 weeks ago globenewswire.com
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
CANTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
1 month ago marketwatch.com
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
1 month ago defenseworld.net
BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGO
BlackRock Inc. acquired a new position in Organogenesis (NASDAQ: ORGO) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The…
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
-
2 months ago benzinga.com
Truist Securities Maintains Hold on Organogenesis Holdings, Lowers Price Target to $2
Truist Securities analyst Ravi Misra maintains Organogenesis Holdings (NASDAQ:ORGO) with a Hold and lowers the price target from $3 to $2.
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
2 months ago benzinga.com
Trade Desk Posts Downbeat Q2 Results, Joins Sezzle, Resmed, Ouster And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after weak Q2 results. Other stocks also lower premarket.
2 months ago benzinga.com
Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket
Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. Stock jumped 30.7% in pre-market trading.
2 months ago marketbeat.com
Organogenesis Q2 Earnings Call Highlights
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for…
2 months ago seekingalpha.com
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…
-
2 months ago benzinga.com
Organogenesis Holdings Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $179.000M-$215.000M vs $282.850M Est
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $270.000 million-$310.000 million to $179.000 million-$215.000 million vs $282.850 million estimate.
2 months ago globenewswire.com
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
3 months ago globenewswire.com
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and…
3 months ago benzinga.com
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Pegasystems Inc (NASDAQ: PEGA) reported lower-than-expected earnings and sales, causing stocks to fall 16% in pre-market trading.
3 months ago benzinga.com
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Nasdaq 100 gains 1%. Danaher Corp (DHR) shares fall 10.1% in pre-market trading. Other stocks also decline.
3 months ago benzinga.com
Ryanair Posts Weak Q1 Results, Joins HDFC Bank And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 results. Other stocks declining in pre-market.
3 months ago globenewswire.com
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
-
3 months ago benzinga.com
Organogenesis' Biologics License Application For ReNu Receives FDA's Acceptance For Review To Treat Pain In Symptomatic Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced…
3 months ago globenewswire.com
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and…
4 months ago seekingalpha.com
Organogenesis: Mesmerized By Wound Care Struggles, Upcoming ReNu Blockbuster Overlooked
Organogenesis is grappling with significant revenue declines in 2026 due to adverse Medicare policy changes impacting its core skin substitute products. 2025 marked a peak year for ORGO, but 2026…
5 months ago benzinga.com
This Suncrete Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top analysts change outlook on top names. Check out analyst ratings page for all changes. RMIX, ABSI, and ORGO get coverage with targets.
-
5 months ago benzinga.com
Truist Securities Initiates Coverage On Organogenesis Holdings with Hold Rating, Announces Price Target of $3
Truist Securities analyst Ravi Misra initiates coverage on Organogenesis Holdings (NASDAQ:ORGO) with a Hold rating and announces Price Target of $3.
5 months ago benzinga.com
Why Estee Lauder Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Estee Lauder (EL) shares jumped 11.8% in pre-market trading after ending discussions with Puig. Other gainers include PCLA, AKTX, LFS, BIYA, QTEX, GOVX, COHN, SQNS, and IMAX.
5 months ago benzinga.com
Deckers Outdoor, UP Fintech And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures rise with Dow gaining 300 points. Deckers Outdoor Corp shares fall after beating Q4 revenue estimates and providing fiscal 2027 guidance.
5 months ago marketbeat.com
Organogenesis Q1 Earnings Call Highlights
Organogenesis NASDAQ: ORGO reported a sharp year-over-year revenue decline in the first quarter of 2026, with executives pointing to significant disruption in the skin substitute market following…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
5 months ago benzinga.com
Forward Air Posts Downbeat Q1 Results, Joins Upwork, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures up, Dow futures gain approx. 100 pts. Forward Air Corp (FWRD) shares down 42.8% in pre-market trading. Other stocks also down.
5 months ago benzinga.com
Forward Air Posts Downbeat Q1 Results, Joins Upwork, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures up, Dow futures gain approx. 100 pts. Forward Air Corp (FWRD) shares down 42.8% in pre-market trading. Other stocks also down.
5 months ago seekingalpha.com
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Organogenesis Holdings Lowers FY2026 Sales Guidance from $350.000M-$420.000M to $270.000M-$310.000M vs $401.200M Est
Organogenesis Holdings (NASDAQ:ORGO) lowers FY2026 sales outlook from $350.000 million-$420.000 million to $270.000 million-$310.000 million vs $401.200 million estimate.
-
5 months ago benzinga.com
Organogenesis Hldgs Q1 Adj. EPS $(0.34) Misses $(0.31) Estimate, Sales $36.250M Miss $43.300M Estimate
Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 209.09 percent decrease over losses…
5 months ago globenewswire.com
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
CANTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the…
6 months ago globenewswire.com
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain If approved, ReNu® will revolutionize treatment options for millions of patients with knee OA pain
6 months ago benzinga.com
What's Going On With Organogenesis Stock On Wednesday?
Wound closure at 12 weeks was a key highlight, indicating the product's efficacy.
6 months ago benzinga.com
What's Going On With Organogenesis Stock On Wednesday?
Organogenesis stock rises after PuraPly AM trial shows improved diabetic foot ulcer closure; RSI signals oversold levels amid weak trend.
6 months ago seekingalpha.com
Organogenesis: Clinical Win De-Risks 2026, Recovery In Sight
Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant…
6 months ago benzinga.com
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win
The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM plus standard of care to standard care alone.
6 months ago benzinga.com
Organogenesis Stock Rockets After Diabetic Foot Ulcer Trial Posts Statistically Significant Win
Organogenesis stock jumps after PuraPly AM trial meets endpoint, while ReNu shows mixed Phase 3 data and advances toward FDA filing.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 months ago benzinga.com
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.
-
6 months ago benzinga.com
Reported Earlier, Organogenesis Reports PuraPly AM Meets Primary Endpoint In Randomized Controlled Trial, Demonstrating Statistically Significant DFU Wound Closure At 12 Weeks
Statistically significant (p<0.0477) DFU wound closure at 12 weeksRCT compared PuraPly®AM plus standard of care to standard of care aloneResults strengthen existing clinical evidence supporting…
6 months ago globenewswire.com
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of…
-
6 months ago benzinga.com
Organogenesis Holdings Completes Type-B Meeting With FDA And Plans to File BLA For ReNu Before The End Of December
Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and…
6 months ago globenewswire.com
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
-
7 months ago benzinga.com
BTIG Reiterates Buy on Organogenesis Holdings, Maintains $8 Price Target
BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Buy and maintains $8 price target.
8 months ago benzinga.com
Organogenesis Holdings Reports Q4 2025 Results: Full Earnings Call Transcript
Organogenesis Holdings Reports Q4 2025 Results: Full Earnings Call Transcript
-
8 months ago benzinga.com
BTIG Maintains Buy on Organogenesis Holdings, Lowers Price Target to $8
BTIG analyst Ryan Zimmerman maintains Organogenesis Holdings (NASDAQ:ORGO) with a Buy and lowers the price target from $9 to $8.